利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.013 秒)

    PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY
    5.
    发明申请
    PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY 审中-公开
    TTK抑制剂化疗的预防生物标志物

    公开(公告)号：WO2016166255A1

    公开(公告)日：2016-10-20

    申请号：PCT/EP2016/058292

    申请日：2016-04-14

    申请人： NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.

    发明人： DE ROOS, Jeroen ,  UITDEHAAG, Joost, Cornelis, Marinus ,  DE MAN, Adrianus, Petrus, Antonius ,  BUIJSMAN, Rogier, Christiaan ,  ZAMAN, Guido, Jenny, Rudolf

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886

    摘要： The present invention provides a method for identifying a tumor - in a human individual or in an animal - that is susceptible to treatment with a TTK inhibitor, said method comprising: a] providing a sample of a tumor; b] determining the presence of a mutated CTNNB1 gene in said tumor sample, wherein said mutation is located in exon 3 of CTNNB1 and whereby the presence of a mutated CTNNB1 gene indicates that the tumor is susceptible to treatment with a TTK inhibitor. In an alternative aspect, step b] of the above defined method is replaced by the step of determining the presence of a mutated CTNNB1 protein in said tumor sample, wherein said mutation is located in exon 3 of CTNNB1 and whereby the presence of a mutated CTNNB1 protein indicates that the tumor is susceptible to treatment with a TTK inhibitor. In a further alternative, step b] comprises determining an altered expression of a CTNNB1 regulated gene, whereby an altered expression of a CTNNB1 regulated gene indicates that the tumor is susceptible to treatment with a TTK inhibitor.

    摘要翻译： 本发明提供了用于鉴定易于用TTK抑制剂治疗的人个体或动物中的肿瘤的方法，所述方法包括：a]提供肿瘤样品; b]确定所述肿瘤样品中突变的CTNNB1基因的存在，其中所述突变位于CTNNB1的外显子3中，由此突变的CTNNB1基因的存在表明肿瘤易于用TTK抑制剂治疗。 在另一方面，上述定义的方法的步骤b]由所述肿瘤样品中确定突变的CTNNB1蛋白的存在的步骤代替，其中所述突变位于CTNNB1的外显子3中，由此存在突变的CTNNB1 蛋白质表明肿瘤易于用TTK抑制剂治疗。 在另一替代方案中，步骤b]包括测定CTNNB1调节基因的改变的表达，由此CTNNB1调节基因的改变的表达表明肿瘤易于用TTK抑制剂治疗。